Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-7547
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis ; volume:21 ; number:1 ; day:26 ; month:1 ; year:2023 ; pages:1-11 ; date:12.2023
Cost effectiveness and resource allocation ; 21, Heft 1 (26.1.2023), 1-11, 12.2023
- Urheber
-
Goudarzi, Zahra
Mostafavi, Mehrdad
Salesi, Mahmood
Jafari, Mojtaba
Mirian, Iman
Hashemi Meshkini, Amir
Keshavarz, Khosro
Ghasemi, Younes
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12962-023-00420-4
- URN
-
urn:nbn:de:101:1-2023040209055388873123
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Goudarzi, Zahra
- Mostafavi, Mehrdad
- Salesi, Mahmood
- Jafari, Mojtaba
- Mirian, Iman
- Hashemi Meshkini, Amir
- Keshavarz, Khosro
- Ghasemi, Younes
- SpringerLink (Online service)
Ähnliche Objekte (12)
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
Thrombospondin-2 and LDH are putative predictive biomarkers for treatment with everolimus in second-line metastatic clear Ccll renal cell carcinoma (MARC-2 study)
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma
Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
Thrombospondin-2 and LDH are putative predictive biomarkers for treatment with everolimus in second-line metastatic clear Ccll renal cell carcinoma (MARC-2 study)
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma
Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
Thrombospondin-2 and LDH are putative predictive biomarkers for treatment with everolimus in second-line metastatic clear Ccll renal cell carcinoma (MARC-2 study)
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma
Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer